It is difficult for organizations to keep up with the ever-evolving precision oncology data. However, without access to this information, it is nearly impossible to stay up to date with new biomarkers, drug developments, or approvals.

That’s where GenomOncology comes in. GenomOncology’s Precision Oncology Platform is designed to yield data-driven insights to improve cancer care. Built to harmonize the latest precision oncology information, this platform contains an extensive set of annotations and ontologies, as well as curated public, licensed, and proprietary content and data sets, including all FDA approvals of targeted therapies and immunotherapies for cancer, all biomarker-based NCCN guidelines, all FDA special status therapies (e.g. Priority Review), and all active clinical trials for cancer.

Through machine learning and proprietary algorithms, the GenomOncology Precision Oncology Platform translates this all-encompassing, complex precision oncology data into actionable insights.